Expert Panel Publishes Recommendations On Appropriate Use Of New Alzheimer’s Treatment, Aduhelm

An expert panel published recommendations on appropriate use of aducanumab (trade name Aduhelm), a recently approved medication to treat cognitive decline due to Alzheimer’s disease. “Aducanumab: Appropriate Use Recommendations” was published online by The Journal of Prevention of Alzheimer’s Disease simultaneously with a session at the Alzheimer’s Association International Conference 2021.

The recommendations are based on a review of clinical trials of aducanumab, updated Food and Drug Administration (FDA) prescribing information and expert consensus. The FDA approved aducanumab on June 7, 2021. The goal of the recommendations is to provide guidance for the safe and effective use . . .